Prelude Therapeutics Incorporated

PRLD · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$19,725-$31,231-$32,085-$28,731
Dep. & Amort.$425$433$435$489
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$3,814$3,832$3,774
Change in WC-$2,572$739-$6,876$4,287
Other Non-Cash$2,757$170$463-$563
Operating Cash Flow-$19,115-$26,075-$34,231-$20,744
Investing Activities
PP&E Inv.$0-$20-$47-$53
Net Acquisitions$0$0$0$0
Inv. Purchases$0-$24,664-$9,463-$7,328
Inv. Sales/Matur.$40,091$36,205$71,696$29,499
Other Inv. Act.$0$0$0$0
Investing Cash Flow$40,091$11,521$62,186$22,118
Financing Activities
Debt Repay.$0-$53-$155-$151
Stock Issued$0$92$0$124
Stock Repurch.$0$0-$5$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$5-$2$0-$7
Financing Cash Flow-$5$37-$160-$34
Forex Effect$809$0$0$0
Net Chg. in Cash$21,780-$14,517$27,795$1,340
Supplemental Information
Beg. Cash$25,752$44,313$16,518$15,178
End Cash$47,532$29,796$44,313$16,518
Free Cash Flow-$19,115-$26,095-$34,278-$20,797